Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results
February 14, 2019 08:30 ET
|
Achaogen, Inc.
-- Company provides update on ZEMDRI® commercialization and launch -- -- Data from both the EPIC and CARE Phase 3 clinical studies of plazomicin are expected in peer-reviewed publication -- SOUTH...
Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield
February 14, 2019 08:30 ET
|
Achaogen, Inc.
-- Plazomicin may be well-suited to play a critical role in biodefense preparedness -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a...
Achaogen Announces FDA Clearance and Launch of the Thermo Scientific QMS Plazomicin Immunoassay
December 10, 2018 08:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting
November 26, 2018 08:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Announces Presentations at Two Investor Healthcare Conferences in November
November 09, 2018 08:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 08, 2018 08:01 ET
|
Achaogen, Inc.
-- Company provides update on ZEMDRITM commercialization and launch -- -- Conference call today at 8:30 a.m. Eastern Time -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Achaogen,...
Achaogen Announces Review of Strategic Alternatives and Corporate Restructuring
November 05, 2018 09:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 8, 2018
November 02, 2018 08:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin
October 17, 2018 08:01 ET
|
Achaogen, Inc.
-- MAA submission for complicated urinary tract infections (cUTI), bloodstream infections, and infections due to Enterobacteriaceae in adult patients with limited treatment options -- SOUTH SAN...
Achaogen Highlights Multiple Plazomicin Presentations at IDWeek 2018
October 03, 2018 08:01 ET
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterial agents...